Recently, several components of the immune system have been targeted in an attempt to reduce inflammation leading to atherosclerosis with anti-interleukin-1 (IL-1) and anti-interleukin-6 (IL-6) targeted therapy showing promising results [5, 6]. Here, IL6 is linked to atherosclerosis.